Neil Woodford Buys Unloved NEXT plc, AstraZeneca plc And Capita PLC

Top fund manager Neil Woodford has been pumping cash into NEXT plc (LON:NXT), AstraZeneca plc (LON:AZN) and Capita PLC (LON:CPI).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

High Street stalwart Next (LSE: NXT) has given shareholders the jitters in recent months, but the latest update from the CF Woodford Equity Income Fund explains why master investor Neil Woodford continues to believe in the company — and has averaged down as the share price has fallen.

As well as backing the FTSE 100 retailer, Woodford has recently bulked-up a number of the fund’s other holdings, including pharma group AstraZeneca (LSE: AZN) and outsourcing specialist Capita (LSE: CPI).

“Exceptional retailer”

Shares of Next were trading as high as £80 last autumn, but began to fall towards the end of the year as unseasonably warm weather persisted ahead of a trading update in early January. There was further weakness following the update, then another big leg down after the company announced its annual results last month.

The results were actually in line with expectations, but the outlook statement sent the market into a tizz. Management highlighted signs of uncertainty in the consumer economy and said its “instinct” was “to prepare ourselves for what could be a difficult year”. As a result, the company revised down its guidance for sales and profits.

Woodford and his team have an interesting take: 

“We see the comments from Next’s management team as negative for the wider retail sector and indeed for consumer cyclical stocks more broadly. But, as far as Next itself is concerned, we think that the market has reacted inappropriately to the update”.

If Woodford is right, you shouldn’t be worried about Next, but you should be worried if you hold shares in other retailers and consumer cyclical stocks generally!

Describing Next as “an exceptional retailer”, Woodford and his team continue to believe the company will deliver “a very attractive long-term total return through a combination of its current dividend yield and continued growth in its free cash flow generation”.

At a share price of around £54.50 — over 30% down from last year’s high — the consensus analyst forecasts give a bumper yield of 7.2% and an attractive price-to-earnings (P/E) ratio of 12.5.

“Groundless share price weakness”

Woodford has been bearish on the oil and mining sectors for a number of years, and is far from convinced that the recent rally is sustainable. He continues to avoid this area due to structural over-supply, the prevailing economic headwinds and his fear that the outlook for Chinese economic growth will further deteriorate.

However, the market’s recent enthusiasm for the oil and mining sectors, has enabled Woodford to add to some stocks in sectors he favours that have seen “groundless share price weakness”. AstraZeneca’s shares have declined by 10% since the start of the year — from above £46 to around £41.50 today. The company is still battling falling sales and earnings, as a result of patent expiries, but Woodford strongly believes that the longer-term future is bright. Astra looks decent value on a P/E of 14.8 with a dividend yield of 4.7%.

In February, Capita reported good results for 2015 and a solid start to the current year, but this is another company whose shares have been weak of late, and one the equity income fund has “continued to build” a position in. Again, with the shares rather depressed at around £10.40, the valuation looks attractive. The P/E is 14 and while the dividend yield of 3.3% isn’t the highest around, consistently strong earnings growth has underpinned a nicely rising payout.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »